Leading the way to safer medication
 Crosscheck  Recommender

Tofacitinib

Description

Tofacitinib is a potent, selective inhibitor of the JAK family. In human cells, tofacitinib preferentially inhibits signalling by heterodimeric cytokine receptors that associate with JAK3 and/or JAK1. Inhibition of JAK1 and JAK3 by tofacitinib attenuates signalling of interleukins and type I and type II interferons, which will result in modulation of the immune and inflammatory response.

ATC Classification

Code
Title
Category
L04AA29
Tofacitinib
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants

Trade names

Trade name
Countries

Australia Austria Canada Cyprus Netherlands

Product Monographs

Monograph
Type
Country
XELJANZ Film-coated tablets
MPI, EU: SmPC